Liang Li. Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator<alt-title>Intracranial Hemorrhage and Acute Ischemic Stroke</alt-title> JAMA: The Journal of the American Medical Association. 2012;307:2600+.
 Parsons Mark, Spratt Neil, Bivard Andrew, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. The New England journal of medicine. 2012;366:1099–1107.
 Alberts Mark J.. Cerebral Hemorrhage, Warfarin, and Intravenous tPA<subtitle>The Real Risk Is Not Treating</subtitle><alt-title>Cerebral Hemorrhage, Warfarin, and Intravenous tPA</alt-title> JAMA: The Journal of the American Medical Association. 2012;307:2637+.
 Bhatia Rohit, Hill Michael D., Shobha Nandavar, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke; a journal of cerebral circulation. 2010;41:2254–2258.
 Fonarow Gregg C., Smith Eric E., Saver Jeffrey L., et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750–758.
 Hacke Werner, Kaste Markku, Bluhmki Erich, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England journal of medicine. 2008;359:1317–1329.
 Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. The New England journal of medicine. 1995;333:1581–1587.